Do GLP-1 Stickers Work? A UK Pharmacist-Led Answer (October 2026)

01 · The core answer

Do GLP-1 stickers work for weight loss?

No, there is no evidence they work in the way prescription GLP-1 treatment does. A sticker sold online under a name such as "GLP-1 patch" is not Mounjaro, not Wegovy and not any other licensed GLP-1 medicine. The name is borrowed because people have heard of the real drugs and want something similar without an injection.

The distinction matters because every impressive weight-loss figure you have seen belongs to a prescription medicine tested in a specific form. Mounjaro, for example, is a pen injection, and the trial results attach to that pen, taken weekly, alongside a reduced-calorie diet and more activity. None of those results transfer to a product that merely uses similar words on its packaging.

What these stickers claim to be and appetite suppressant stickers are marketed in near-identical language, and neither has the clinical evidence of a licensed treatment.

02 · Side by side

Stickers versus prescription GLP-1 treatment

03 · Your next step

What should you do if you are tempted by a sticker?

Decide first whether you meet the criteria for prescribed treatment, because that is the real choice. If you do not, a sticker will not fill the gap, and the safer steps are food, activity and speaking to your GP or pharmacist about weight management.

If you do meet the criteria, an assessed, licensed route is available. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. The Mounjaro pen starts with the 2.5mg strength: your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99), and all six doses are in stock. Our weight loss clinic page explains the wider options, including Wegovy, and a prescriber can tell you if treatment is appropriate for you at all.

If the answer is no, that is a valid outcome. Unsuitable orders are refunded automatically, and you will have spent nothing on a product that was never going to help.

04 · What stickers claim

What GLP-1 stickers claim to do

GLP-1 stickers are small adhesive patches marketed as a needle-free way to curb appetite and lose weight. The pitch is simple: stick one on your arm or stomach, and let it work through the skin. Names vary, and so do the packaging and the influencer endorsements, but the promise is nearly always the same.

What they do not tell you is what is actually inside. Products of this type are generally described as containing plant extracts, vitamins or other supplement-style ingredients. Some leave the ingredient list vague, and some borrow phrases such as "GLP-1 support" so that the label sounds clinical without saying the product is a GLP-1 medicine. "Supporting" a hormone is not the same as supplying a drug that acts on its receptor.

The marketing often goes further. You will see "nature's Ozempic" style slogans, before-and-after photographs, and dramatic weight-loss claims presented as typical. Anyone can publish a photograph; only a controlled trial can show what a product does on average across many people.

It also helps to understand why the format is attractive. Many people dislike the idea of injecting, worry about side effects, or feel uncomfortable seeking a prescription. A sticker removes all of those barriers, which is exactly why sellers target them. The convenience is real; the effect is the unproven part.

The label is not regulated in the way a medicine name is, so the buyer cannot assume that it means what they hope.

Where the claim is that a sticker "works", ask what working means. Appetite change, a lower number on the scale for a week, and sustained, measured weight reduction are very different outcomes, and only the last is clinically meaningful. A seller who blurs those outcomes is selling hope rather than a result.

05 · Why a patch is not an injection

Why a sticker cannot do what a pen does

A sticker is not a licensed form of any GLP-1 medicine, and that is the central problem. The treatments we supply are medicines that were developed, tested and licensed in a particular form. Mounjaro is described in its product information as a once-weekly injectable prescription medicine made by Eli Lilly, supplied as a pre-filled multi-dose pen.¹ Tablet versions of other GLP-1 medicines exist too, but they are separate licensed products with their own product information, not stickers.

Each strength is a defined amount, and the dose ladder is part of how the medicine is used safely. A sticker has no equivalent: you cannot know how much active substance, if any, reaches your body, and dosing is not standardised.

Next, consider what the real medicine does. Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ That is a precise pharmacological action produced by a specific molecule. A product that does not contain that molecule cannot produce that action, whatever its label says.

This is why we describe stickers as unlicensed in this context rather than as a gentler version of the same thing. There is no weaker dose of tirzepatide hiding in a patch. Either the product contains a licensed medicine, in which case it would need a prescription and a regulated supply chain, or it does not, in which case it is not a GLP-1 treatment.

You can read more about the real mechanism in our guides on how GLP-1 medicines work and how GLP-1 agonists work. Both explain why appetite, fullness and blood-sugar handling change on treatment, and why those changes depend on the medicine reaching the body in its tested form.

One further point: a prescriber chooses a medicine, a dose and a monitoring plan around your health history. That decision process is part of the treatment. A sticker bypasses it entirely, which removes the safety checks as well as the effect.

None of this means that the idea of a needle-free route is impossible in principle; it means that no such product is available to buy as a sticker today with evidence behind it. Until a regulator licenses one, any patch claiming to be a GLP-1 treatment should be treated with scepticism.

06 · What real treatment achieves

What real GLP-1 treatment achieves in trials

The weight-loss results people associate with GLP-1 treatment come from trials of licensed medicines, and they are worth stating accurately. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² That sentence matters as much as the headline figure. Nobody should read those percentages as a promise, and nobody should read them as a description of what any other product does.

The same trial reported that at 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.² Again, these belong to tirzepatide, tested in a controlled setting, and to nothing else.

A worked example makes the scale clearer without overpromising. For someone starting at 100 kg, 20.9% is about 21 kg. That is a trial average for the highest dose over a long period, not a forecast for any individual, and it relied on medicine, diet and activity together.

Beyond the scales, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes, not promises, but they explain why prescribers talk about weight management as health management rather than appearance.

A genuine treatment is the benchmark any weight-loss product should be held to. A genuine treatment can show you the trial, the population, the duration and the average result, and it will tell you plainly that results differ between people.

When you see a patch advertised alongside the names Mounjaro, Ozempic or Wegovy, remember that the association is the marketing, not the evidence. Ozempic is semaglutide licensed for type 2 diabetes — it is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label. Our guide on whether GLP-1 actually works goes through the genuine evidence in more depth, including what realistic outcomes look like.

A fair summary: licensed GLP-1 and GIP/GLP-1 medicines have substantial published evidence, with caveats; stickers have marketing.

07 · Realistic pace of results

How fast does real treatment work, and why that matters for sticker claims?

Real treatment is gradual, which is one of the clearest tests of a sticker's claims. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.

If a licensed medicine, tested properly, builds progress over months, then a product promising rapid transformation within days is either measuring something else, such as water, or exaggerating. We would treat any "lose weight fast" patch with caution for exactly that reason.

Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at this stage are modest compared with the headline figures: in SURMOUNT-1, average weight loss built month by month, with the full 15–21% averages measured at 72 weeks, not 12.² A sensible three-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.

The first weeks also differ widely between people. Some notice appetite change and early loss in week one, others feel little until a higher dose, and both are normal. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.¹

Plateaus are normal as well. Weight loss on Mounjaro is not linear, and plateaus of a few weeks are expected as the body adapts to a lower weight. Within the licence, the responses are to review food intake honestly because portions drift back up, protect protein and activity, check the basics such as sleep and alcohol, and discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum. A plateau is not a reason to double doses or add unlicensed products.¹

That last sentence deserves emphasis for anyone tempted to layer a sticker on top of treatment, or to use one when progress stalls. Adding an unregulated product is not the medically sensible response to a plateau.

There is also a built-in review point. Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹ A sticker has no review point, no one to ask, and no threshold at which someone tells you it is not working.

08 · Supplements and herbal ingredients

What about the herbal ingredients in these patches?

Herbal and supplement ingredients are not GLP-1 medicines, whatever the sticker's name suggests. Patches of this kind are commonly marketed alongside ingredients such as berberine, or described as "nature's Ozempic". That phrase is a marketing device, not a pharmacological description. It implies equivalence with a prescription drug that the product has not demonstrated.

Dosing is not standardised for supplements, and the products are available cheaply without assessment. That cheapness is a point about safety and evidence rather than value: a low-cost supplement with no clinical oversight is not a lower-priced version of a prescribed treatment. It is a different kind of product altogether.

There are a few reasons the comparison breaks down. First, a supplement is not required to show that it reduces weight before it goes on sale. Second, ingredient amounts can vary between batches and brands, and in a patch there is no reliable way for you to know how much is released. Third, nobody monitors you, so side effects can go unnoticed, and interactions with medicines you already take are not checked.

Some people feel an effect from a supplement, and that is not impossible.

It is also worth separating the question of whether a herbal ingredient does anything at all from the question of whether it replicates a GLP-1 medicine. The second is clearly no. The first is a matter for the supplement's makers to evidence, and a patch format adds an extra layer of uncertainty about what reaches the body.

If you are already taking prescription medicines, including insulin or other diabetes treatments, speak to a pharmacist or prescriber before adding any supplement. Doses of diabetes medicines may need adjusting when weight and appetite change, and unsupervised additions make that harder to manage safely.

The takeaway is consistent: the label "GLP-1" on a supplement describes a hope, not a drug.

09 · Risks and red flags

Risks and red flags when buying weight-loss stickers

The main risks are wasted money, skin reactions, unknown ingredients and delayed proper care. Because these products sit outside the medicines system, nobody checks the label against what is inside, and there is no prescriber to ask when something feels wrong.

Skin irritation is a practical concern with any adhesive worn for long periods, and some people are sensitive to adhesives or to plant-derived ingredients. If a patch causes redness, itching or a rash, remove it and speak to a pharmacist.

There is also the opportunity cost. Someone who would qualify for effective, licensed treatment may spend months on a product that was never going to deliver, and that is time in which weight-related health risks continue. That is a quiet harm, but a real one.

Watch for these warning signs when you assess any seller:

• The product claims to be GLP-1, semaglutide or tirzepatide but is sold without a consultation or prescription.
• Promises of specific results or dramatic weight-loss claims in a short time.
• No named, registered pharmacy and no way to check one. You can check a UK pharmacy on the GPhC register; ours is GPhC 9012878.
• Vague or missing ingredient lists.
• Prices and dosing that are not standardised, with no review or aftercare.

Counterfeit and unlicensed products are a wider issue in the weight-loss market. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme, and it is the place to look if you are worried about a product.⁷ If you have taken any product and experience a side effect, you can report it through the MHRA Yellow Card scheme.¹⁹

Anyone offering real tirzepatide or semaglutide without a consultation or prescription is breaking the rules, and you should walk away. Genuine supply of Mounjaro comes via a registered pharmacy after a clinical review. Our supply is official LillyDirect supply, with genuine KwikPens delivered in temperature-controlled packaging.

If you are pregnant, planning pregnancy, breastfeeding or have a medical condition, speak to a pharmacist or your GP before using any weight-loss product. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Newly noticed symptoms after starting anything should be discussed with a clinician.

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · NHS and private routes

The genuine routes to GLP-1 treatment: NHS and private

There are two legitimate routes to GLP-1 treatment in the UK, and neither involves a sticker. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁶ If you think you may be eligible on the NHS, ask your GP. NHS access to Wegovy runs through specialist weight-management services, so ask your GP about that too.

The second route is a regulated online pharmacy. That means a pharmacy on the GPhC register, a consultation, and a prescriber who decides whether treatment is suitable.

• Free online consultation. A short health questionnaire, no charge, no obligation.
• Prescriber review. Reviewed by a GPhC-registered prescriber, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Dispensing and delivery. Dispensed by our registered pharmacy, with same-day dispatch when ordered by 3pm and free next-day tracked delivery in discreet, temperature-controlled packaging.

The consultation is free, and the price shown is the price paid, with no hidden fees. Prices were checked 10 October 2026. New customers save £40 on their first order with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25). We do not use subscriptions; repeat orders re-check suitability and nothing ships automatically.

Aftercare is part of the service. Ongoing monthly reviews, dose titration and follow-up assessments are carried out by the prescribing team, with side-effect support if you need it. For anyone comparing this with a sticker, that is the real difference: a clinician is involved at every step.

You can see current pricing and start a consultation on the Mounjaro pen page, or explore the Wegovy pen if you want to compare. Support is available Monday to Friday during office hours by email, account chat or phone.

If the NHS route suits you, use it. If it does not, or you cannot wait, the regulated private route offers a licensed medicine rather than a lookalike product.